Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

Novartis India Ltd - 500672 - Intimation Under Reg. 30 Of SEBI (LODR) Regulations 2015 Pertaining To Notice Of Demand Under The Income Tax Act, 1961

 This is to inform that the Company has received certain notices of demand from the office of 'Joint Commissioner of Income Tax (OSD) (TDS)' in respect of Orders passed under sec. 201(1) / 201(1A) of the Income Tax Act, 1961 pertaining to short deduction of TDS (Tax Deduction at Source) on certain transactions of the Company. The details of the same are elaborated in the attached letter. You are requested to take note of the said information in your records.
06-03-2020
Bigul

NOVARTIS INDIA LTD. - 500672 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Please note that in terms of the applicable provisions of the SEBI Listing Regulations, the Company has received intimation regarding loss of share certificate from the following shareholder: Stop transfer date - March 4, 2020 Folio No. M000521 Name of the shareholder - Manjulaben Rameshchandra Mali Certificate No. 433145 Distinctive No. 31908961 -31908964 No. of shares - 4 Reason - Lost by the holder The Registrar and Share Transfer Agent of the Company i.e. Link lntime India Private Limited has received a request letter from the abovementioned shareholder and have informed the Company about the same today i.e. on March 5, 2020. Further, subject to completion of required formalities by the shareholder, the Company will issue duplicate share certificate in lieu thereof. Thanking you
05-03-2020
Bigul

NOVARTIS INDIA LTD. - 500672 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Dear Sirs, Please note that in terms of the applicable provisions of the SEBI Listing Regulations, the Company has received intimation regarding loss of share certificate from the following shareholder: Stop transfer date: February 25, 2020 Folio No. 02016532 Name - A N RAJAN Certificate No. 8983 Distinctive number - 3579077 - 3579226 No. of shares - 150 Reason - Lost by holder The Registrar and Share Transfer Agent of the Company i.e. Link lntime India Private Limited has received a request letter from the abovementioned shareholder and have informed the Company about the same today i.e. on February 26, 2020. Further, subject to completion of required formalities by the shareholder, the Company will issue duplicate share certificate in lieu thereof. Thanking you
26-02-2020

Novartis, DNDi ink drug development pact to treat kala azar

 DNDi will lead Phase II and III clinical development, with the first Phase II study scheduled to start in early 2021 in India
25-02-2020
Bigul

Novartis launches digital innovation hub in Hyderabad

 The Hyderabad centre is the Novartis' fourth digital hub. The three others are in San Francisco (US), Paris (France) and London (UK)
19-02-2020
Bigul

Supplies from China stable for now, but monitoring situation: Novartis' Vas Narasimhan

 Even as the coronavirus outbreak casts a shadow of uncertainty on supplies sourced from China, Novartis' Global Chief Executive Officer Vasant (Va
17-02-2020
Bigul

Novartis India Ltd - 500672 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Dear Sirs, Apropos the subject matter quoted above, please find enclosed herewith the copies of the newspaper Notices in 'Financial Express' and 'Navshakti' on February 12, 2020. This is for your information and record. Thanking You.
12-02-2020

Novartis India share price falls 2% after Q3 profit declines 40% to Rs 7 cr

 The stock witnessed spurt in volume by more than 1.24 times and was trading with volumes of 10,070 shares, compared to its five day average of 9,685 shares, an increase of 3.98 percent.
12-02-2020
Bigul

Novartis India Ltd - 500672 - Change In Contact Details Of Key Managerial Personnel Of Novartis India Limited ('The Company') Authorised For The Purpose Of Determining The Materiality Of An Event Or Information And For Making The Disclosures To The Stock Exchanges

 Kindly note that in terms of the provisions of Regulation 30(5) of the SEBI Listing Regulation, the Board of Directors of the Company has authorised following Key Managerial Personnel of the Company for the purpose of determining the materiality of an event or information and for purpose of making disclosures to the Stock Exchanges under Regulation 30 of SEBI Listing Regulations. Details of the same is attached herewith.
11-02-2020
Bigul

Novartis India Ltd - 500672 - Results - Financial Results For The Quarter Ended December 31, 2019

 Kindly note that the Board of Directors of the Company has in its meeting held today i.e. on Tuesday, February 11, 2020 ("said meeting"), inter alia considered and approved the Unaudited Financial Results of the Company for the third quarter and nine months ended on December 31, 2019. The said Meeting commenced at 11:00 a.m. and concluded at 5:00 p.m. Further, in terms of the applicable provisions of SEBI Listing Regulations, please find enclosed herewith: a. the Unaudited Financial Results; b. Limited Review Report dated February 11, 2020, issued by the Statutory Auditors of the Company with respect to the Unaudited Financial Results and taken on record by the Board of Directors of the Company. The above is for your information and the same is also available on the Company''s website i.e. www.novartis.in Thanking you
11-02-2020
Next Page
Close

Let's Open Free Demat Account